Merus(US:MRUS)2020-05-29 17:37Company Overview - Merus is developing multispecific antibody therapies for oncology, based on the human IgG format[6, 46] - The company's Multiclonics® platform enables high-throughput discovery and engineering of Biclonics® and Triclonics™[6, 9, 45, 46] - Merus has strategic collaborations and license agreements with Incyte, Betta, Simcere, and Ono[6, 43, 46] - Zenocutuzumab (Zeno) NRG-1 phase 1/2 clinical data update is expected by the end of 2020[6, 23, 46] Zenocutuzumab (MCLA-128) Program - Zenocutuzumab (HER3 x HER2 bispecific) shows promising early clinical activity in patients with NRG1+ cancers[6, 12] - In a pancreatic cancer patient, Zeno treatment resulted in a 44% decrease in CA19-9 levels and a 54% reduction in size[17] - Clinical data reported by MSKCC at the 2019 AACR-NCI-EORTC International Conference showed a 54% partial response (PR) in pancreatic cancer and 25% stable disease (SD) and 41% PR in lung cancer[19] - The eNRGy clinical trial and Early Access Program for Zeno in NRG1+ cancers are ongoing[12, 22, 23] Other Pipeline Programs - MCLA-158 (Lgr5 x EGFR bispecific) is in a global phase 1 clinical trial for solid tumors and demonstrates superior selectivity for tumor-derived organoids[11, 29, 31] - MCLA-145 (CD137 x PD-L1 bispecific) is in a global phase 1 trial in partnership with Incyte, targeting PD-L1 positive tumor cells[11, 32, 34, 35]